Jonah Feldman

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.

A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.

Cilta-cel achieved complete, sustained responses without induction therapy in the precursor disease to multiple myeloma.

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with relapsed Ewing sarcoma.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

The oral gamma secretase inhibitor varegacestat improved progression-free survival and overall response rate vs placebo; full results to be presented at ASCO.

The BCMA-CD3 bispecific antibody outperformed daratumumab plus pomalidomide and dexamethasone in double-class exposed patients.

The DNA ImmunoBody therapy improved efficacy when added to ipilimumab and nivolumab, with a registrational phase 3 trial expected to begin later this year.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

The target date for the FDA's decision on isatuximab via on-body injector is now July 23, 2026.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

The FDA granted FTD to OPN-6602, an oral EP300/CBP inhibitor currently used in a first-in-human phase 1 trial.

Oral darovasertib plus crizotinib doubled PFS and boosts responses in first-line HLA-A*02:01–negative metastatic uveal melanoma; FDA submission process is underway.

AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with older age and frailty.

The FDA did not grant accelerated approval to the oncolytic virus-based therapy RP1 in combination with nivolumab for patients with advanced melanoma.

Results of a single-center study showed positive outcomes of reduced-intensity conditioning for tumor-infiltrating lymphocytes in melanoma.

CB-011, an allogeneic CAR T product, received RMAT designation as treatment for multiple myeloma based on strong dose expansion data.

DOMMINO-1 evaluates oral triplet therapy including a new mechanism of action in relapsed/refractory multiple myeloma.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

The first patient recieved the novel investigational molecular glue degrader cemsidomide plus elranatamab for multiple myeloma.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

Adding itacitinib to posttransplant cyclophosphamide and tacrolimus proved safe and well tolerated, with low GVHD rates and no nonrelapse mortality.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.